Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

BioNTech SE - American Depositary Shares (NQ: BNTX )

119.83 -2.95 (-2.40%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
65 66 Next >
Expert Ratings for BioNTech
Via Benzinga
COVID Is Making a Comeback: Should You Buy These 2 Stocks?
Can these companies keep up their recent momentum? 
Via The Motley Fool
Exposures COVID-19
Novavax (NVAX) Stock Is Getting Ready to Rally Again
Novavax only has an Emergency Use Authorization and faces a struggle to get paid for its protein-based Covid shot. 
Via InvestorPlace
Exposures COVID-19
Why Moderna, BioNTech SE, and Novavax Surged Today
The companies have developed vaccines for the current dominant strain of COVID, and the Biden administration is getting behind a new booster campaign. 
Via The Motley Fool
Exposures COVID-19
BioNTech Unusual Options Activity For August 21
Via Benzinga
Moderna, BioNTech And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Dow Jones falling around 150 points on Monday. Here are some big stocks recording gains in today’s session. Genelux Corporation (NASDAQ: GNLX) gained 19.2% to $28.58.... 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With BioNTech (BNTX) Stock?
BioNTech SE - ADR (NASDAQ:BNTX) shares are trading higher by 4.66% to $106.51 Wednesday morning as the stock continues to rebound after falling on Monday. 
Via Benzinga
What's Happening With BioNTech (BNTX) Stock?
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 3.28% to $101.73 Tuesday afternoon as the stock rebounds after falling on Monday. 
Via Benzinga
BioNTech Se (BNTX) Q2 2023 Earnings Call Transcript
BNTX earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33. 
Via Benzinga
Covid Vaccine Rally Dashed As Pfizer, Moderna Give Back Gains On Eris' Advance
The companies are hoping to launch their updated Covid shots in September. 
Via Investor's Business Daily
Exposures COVID-19
Moderna, Pfizer's Updated COVID Shot Shows Effectiveness Against 'Eris' Variant In Early Human, Preclinical Studies
Moderna Inc (NASDAQ: MRNA) announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season showed a significant boost in neutralizing antibodies... 
Via Benzinga
Exposures COVID-19
Why BioNTech Stock Was Sinking Today
While the waning of the COVID pandemic is a positive development for the world, it's left the German biotech struggling. 
Via The Motley Fool
Why Moderna Stock Sunk Today
Moderna, Inc. (NASDAQ: MRNA) shares are trading lower on Monday. 
Via Benzinga
BioNTech Skids As Covid Vaccine-Maker's Sales Plummet And Miss Forecasts
The company kept its sales outlook for the year, however. 
Via Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
This article points you to three undervalued biotech stocks that have the potential to deliver stellar returns for patient investors. 
Via InvestorPlace
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
From BioNTech SE
Via GlobeNewswire
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
Meet Eris, The COVID Variant Behind A Summer Resurgence In Cases: 3 Drugmakers Prep Fall Booster Shots
Via Benzinga
Exposures COVID-19
Preview: BioNTech's Earnings
Via Benzinga
Analyst Ratings for BioNTech
Via Benzinga
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories
Benzinga 
Via Benzinga
BioNTech Slips Into Quarterly Loss As Q2 Revenue Evaporates, Cuts R&D Spending For FY23
BioNTech SE (NASDAQ: BNTX) has reported Q2 revenues of €167.7 million, sharply down from €3.2 billion a year ago 
Via Benzinga
US Stocks Eye Rebound After Big Earnings, But Inflation Data Looms: Analyst Says 3 Factors Can Take S&P 500 Past 4,800
US stocks look set for a cautious start as the week's inflation data will likely keep traders on tenterhooks. 
Via Benzinga
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work.
The company hopes to launch an updated Covid booster shot this fall. But there are several complications. 
Via Investor's Business Daily
BioNTech Completes Acquisition of InstaDeep
From BioNTech SE
Via GlobeNewswire
Analyst Initiates Arcturus: Sees Attractive Growth Trajectory with Vaccine Franchise Despite Competition
William Blair analyst Myles Minter has initiated coverage of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) with an Outperform rating and a fair  
Via Benzinga
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
From BioNTech SE
Via GlobeNewswire
Week In Review: Novartis In $1 Billion Deal For DTx Pharma
Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching... 
Via Talk Markets
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.